Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

May 10, 2017

Understanding Today’s CAR-T Cell Therapy Manufacturing Challenges

CAR-T cell therapy presents numerous challenges for cell therapy developers who are looking to move towards commercialization. The move from development to commercial ...

April 25, 2017

Planning Ahead: Selecting Appropriate Source Materials for Cell-Based Therapy Manufacturing

Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, ...

March 7, 2017

Safety First: Shipping Cell Therapy Materials

Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies ...

February 16, 2017

Challenges and Optimization of Apheresis Collection

On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as ...

September 13, 2016

The Cold Truth: Cryopreservation of Final Product in Cell Therapy Manufacturing

While using cell therapies that have a short shelf-life due to a “fresh” final product (meaning the product is not designed for long-term storage) is perfectly ...

June 22, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 3

This is the third in a three-part series (read Part 1 and Part 2 for the complete picture). As you approach cell therapy commercialization—having traveled what is still ...

June 15, 2016

Precious Cargo: Challenges in the Cell Therapy Transportation Supply Chain

The following is a guest blog by Kevin O’Donnell, Vice President, Cold Chain Standards, Practices & Compliance, BioLife Solutions As forecast by the White House 2012 ...

June 8, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 2

This is the second in a three-part series (Part 1 can be found here). As you enter this mid-phase of development, we reflect on these words from Albert Einstein: “In the ...

May 25, 2016

Cell Therapy Manufacturing Challenges and Solutions, Phase by Phase--Part 1

If you’re reading this, you’ve no doubt already discovered that cell therapy manufacturing comes with its share of specific challenges, no matter what phase of ...

Previous All Posts Next